Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development

Assembly Biosciences, Inc. remains a Buy as Gilead licensed its HPI program, triggering a $35M payment and potential $330M in milestones. Phase 2 trials for both the HPI program (ABI-5366/1179) and HDV candidate ABI-6250 are expected to initiate by end of 2026, with interim catalysts ahead. ABI-6250 aims to be the first oral HDV therapy, addressing an unmet need with positive phase 1a data and a favorable safety profile supporting daily dosing.